Rigel Pharmaceuticals
RIGL • NASDAQ
Rigel Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Raul R. Rodriguez, with a market cap of $476.8M.
CEORaul R. Rodriguez
Next Earnings
Upcoming earnings announcement for Rigel Pharmaceuticals
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.87
Revenue Estimate
$63.2M
Earnings History
Past 12 earnings reports for Rigel Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | $1.12Est: $1.25 | -10.4% | $69.8MEst: $69.1M | +1.0% |  10-K |
| Nov 4, 2025 | Q3 2025 | $1.46Est: $0.85 | +71.8% | $69.5MEst: $61.8M | +12.5% | 10-Q |
| Aug 5, 2025 | Q2 2025 | $3.28Est: $1.63 | +101.2% | $101.7MEst: $75.1M | +35.4% | 10-Q |
| May 6, 2025 | Q1 2025 | $0.63Est: $0.09 | +600.0% | $53.3MEst: $43.9M | +21.5% | 10-Q |
| Mar 4, 2025 | Q4 2024 | $0.80Est: $0.55 | +45.5% | $57.6MEst: $57.6M | +0.0% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.70Est: $0.06 | +1066.7% | $55.3MEst: $41.9M | +31.9% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.06Est: -$0.29 | +79.3% | $36.8MEst: $33.4M | +10.2% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.50Est: -$0.30 | -66.7% | $29.5MEst: $31.3M | -5.6% | 10-Q |
| Mar 5, 2024 | Q4 2023 | $0.00Est: -$0.30 | +100.0% | $35.8MEst: $34.1M | +5.0% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.30Est: -$0.70 | +57.1% | $28.1MEst: $27.2M | +3.4% | — |
| Aug 1, 2023 | Q2 2023 | -$0.40Est: -$0.80 | +50.0% | $26.9MEst: $26.0M | +3.3% | 10-Q |
| May 2, 2023 | Q1 2023 | -$0.80Est: -$1.00 | +20.0% | $26.1MEst: $24.1M | +8.3% | — |